Editas Medicine, Inc. | $EDIT Stock | Shares Tumble Down on Poor Q1 Earning Results

0
193
Editas Medicine
Share this:Share on FacebookTweet about this on TwitterPin on PinterestShare on Google+Email this to someone

Editas Medicine, Inc. (NASDAQ: EDIT)

 

 

Editas Medicine, Inc. (EDIT), a genome editing company yesterday reported their first quarter 2017 financial results. The company reported a first quarter loss of $31.1 million.

EDIT reported first quarter adjusted earnings of a loss of $0.85 per share which fell short of analyst expectations of a loss of $0.62 per share. EDIT reported first quarter revenues of $682,000.         

 

Editas Medicine, Inc. CEO’s  Comments

“We made outstanding progress this quarter building our business for the long term, including forming a strategic alliance with Allergan in ocular diseases, cementing our unmatched intellectual property position with a favorable USPTO decision, and doubling our cash runway,” said Katrine Bosley, President and Chief Executive Officer of Editas Medicine.  “These achievements represent significant strides forward in positioning Editas Medicine to execute our vision to build a company that pioneers a broad new category of genomic medicines.”  Globe Newswire

EDIT Technical Analysis

Editas Medicine
Editas Medicine Chart

EDIT opened trading yesterday at $20.02 which was up from the previous day’s trading close of $19.29. EDIT closed trading yesterday at $20.01 and crashed down after market to $18.88, equivalent to a 6% decrease from the closing price.

Taking a look at the daily chart we can see the last time EDIT traded below these levels we have to go back to May 11th when it traded at $18.51. It’s higher priced than the usual penny stocks that I trade but there could still be plenty of opportunity for a trade here.

Taking a closer look at the daily chart we can see that before the spike down EDIT had already been in an overall downward trend dating back to February 21st when it traded at $27.27. EDIT has a float of 20.59 million shares and traded below the normal daily trading volume on Monday.

For trading purposes, I would like to see EDIT open trading on Tuesday below $19.25 and if it does I would be looking to take a short position at the bell. My stop loss would be $0.20 from my entry position fearing anything more than that and the stock would start to fill in the gap down.

 

Company Profile

Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases.

The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.  Yahoo Finance

 

 

IMAGE CREDIT

SHARE
Previous articleEconomic Calendar & Watch List 5/15/2017
Next articleJack In The Box | $JACK Stock | Shares Explode On Earnings Release
Legal Disclaimer – This is not meant to be a recommendation to buy or to sell securities nor an offer to buy or sell securities. Before selling or buying any stock or other investment you should consult with a qualified broker or other financial professional. The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author has no business relationship with any company whose stock is mentioned in this article nor is receiving compensation from any of the companies mentioned.

NO COMMENTS